$CYRX
Cryoport, Inc.

2020 Q2 Form 10-Q Financial Statement

#000110465920092668 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q2
Revenue $9.389M $9.774M $8.464M
YoY Change 10.93% 46.91% 82.93%
Cost Of Revenue $4.262M $4.516M $4.125M
YoY Change 3.32% 41.17% 94.28%
Gross Profit $5.127M $5.258M $4.338M
YoY Change 18.19% 52.23% 73.24%
Gross Profit Margin 54.61% 53.8% 51.25%
Selling, General & Admin $9.026M $7.111M $6.102M
YoY Change 47.92% 39.3% 34.99%
% of Gross Profit 176.05% 135.24% 140.66%
Research & Development $1.947M $1.733M $540.9K
YoY Change 259.93% 253.97% 20.58%
% of Gross Profit 37.98% 32.96% 12.47%
Depreciation & Amortization $850.0K $824.0K $500.0K
YoY Change 70.0% 174.15% 163.16%
% of Gross Profit 16.58% 15.67% 11.53%
Operating Expenses $10.97M $8.844M $6.643M
YoY Change 65.19% 58.09% 33.69%
Operating Profit -$5.845M -$3.586M -$2.304M
YoY Change 153.69% 67.49% -6.53%
Interest Expense $398.0K $2.000K $333.9K
YoY Change 19.19% -99.41%
% of Operating Profit
Other Income/Expense, Net $93.00K -$323.0K $119.4K
YoY Change -22.14% -453.11% 1577.54%
Pretax Income -$5.753M -$3.909M -$2.519M
YoY Change 128.4% 63.71% 2.47%
Income Tax $50.00K $33.00K $9.624K
% Of Pretax Income
Net Earnings -$5.803M -$3.942M -$2.528M
YoY Change 129.5% 65.15% 2.33%
Net Earnings / Revenue -61.81% -40.33% -29.87%
Basic Earnings Per Share -$0.15 -$0.11
Diluted Earnings Per Share -$151.5K -$104.9K -$81.14K
COMMON SHARES
Basic Shares Outstanding 30.57M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $208.2M $97.40M $94.70M
YoY Change 119.85% 105.92% 373.5%
Cash & Equivalents $44.33M $50.62M $80.64M
Short-Term Investments $191.2M $90.90M $15.30M
Other Short-Term Assets $900.0K $1.000M $500.0K
YoY Change 80.0% 42.86% 0.0%
Inventory $538.4K $500.0K $300.0K
Prepaid Expenses
Receivables $7.039M $6.100M $6.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $216.7M $105.0M $101.7M
YoY Change 113.06% 100.19% 319.73%
LONG-TERM ASSETS
Property, Plant & Equipment $13.70M $18.50M $14.50M
YoY Change -5.5% 261.0% 377.19%
Goodwill $11.00M $11.00M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K $400.0K
YoY Change 25.0% 25.0% 0.0%
Total Long-Term Assets $36.09M $35.10M $31.40M
YoY Change 14.94% 377.9% 795.03%
TOTAL ASSETS
Total Short-Term Assets $216.7M $105.0M $101.7M
Total Long-Term Assets $36.09M $35.10M $31.40M
Total Assets $252.8M $140.1M $133.1M
YoY Change 89.91% 134.3% 379.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.500M $3.200M $3.400M
YoY Change 91.18% 39.13% 54.55%
Accrued Expenses $2.500M $3.500M $2.100M
YoY Change 19.05% 66.67% 133.33%
Deferred Revenue $330.3K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K $0.00
YoY Change
Total Short-Term Liabilities $9.442M $7.100M $5.700M
YoY Change 65.64% 56.67% 81.94%
LONG-TERM LIABILITIES
Long-Term Debt $111.1M $100.0K $14.70M
YoY Change 655.78% -99.32%
Other Long-Term Liabilities $5.500M $5.600M $3.900M
YoY Change 41.03% 250.0% 1850.0%
Total Long-Term Liabilities $116.6M $5.700M $18.60M
YoY Change 526.88% -65.03% 9200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.442M $7.100M $5.700M
Total Long-Term Liabilities $116.6M $5.700M $18.60M
Total Liabilities $126.1M $12.80M $24.40M
YoY Change 416.88% -38.72% 635.71%
SHAREHOLDERS EQUITY
Retained Earnings -$169.1M
YoY Change
Common Stock $295.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $126.7M $127.3M $108.8M
YoY Change
Total Liabilities & Shareholders Equity $252.8M $140.1M $133.1M
YoY Change 89.91% 134.3% 379.84%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q2
OPERATING ACTIVITIES
Net Income -$5.803M -$3.942M -$2.528M
YoY Change 129.5% 65.15% 2.33%
Depreciation, Depletion And Amortization $850.0K $824.0K $500.0K
YoY Change 70.0% 174.15% 163.16%
Cash From Operating Activities -$1.370M $1.059M -$1.060M
YoY Change 29.25% -658.54% -16.54%
INVESTING ACTIVITIES
Capital Expenditures -$1.990M $596.0K -$1.480M
YoY Change 34.46% -46.83% 105.56%
Acquisitions
YoY Change
Other Investing Activities -$117.1M $80.00K -$19.94M
YoY Change 487.01% -101.77%
Cash From Investing Activities -$119.1M -$542.0K -$21.42M
YoY Change 455.79% -90.41% 2875.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 114.1M 2.864M 70.36M
YoY Change 62.21% 121.94% 2253.18%
NET CHANGE
Cash From Operating Activities -1.370M 1.059M -1.060M
Cash From Investing Activities -119.1M -542.0K -21.42M
Cash From Financing Activities 114.1M 2.864M 70.36M
Net Change In Cash -6.290M 3.388M 47.88M
YoY Change -113.14% -174.44% 4688.0%
FREE CASH FLOW
Cash From Operating Activities -$1.370M $1.059M -$1.060M
Capital Expenditures -$1.990M $596.0K -$1.480M
Free Cash Flow $620.0K $463.0K $420.0K
YoY Change 47.62% -135.33% -176.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 cyrx Mechanical And Liquid Nitrogen Freezers Ownership Interest
MechanicalAndLiquidNitrogenFreezersOwnershipInterest
0.25
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38778015
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44326038
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001124524
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38565193
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37339787
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34632
dei Entity Registrant Name
EntityRegistrantName
CRYOPORT, INC.
dei Entity Address Address Line1
EntityAddressAddressLine1
Nevada
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0313393
dei Entity Address City Or Town
EntityAddressCityOrTown
Brentwood
dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37027
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
470-2300
dei Security12b Title
Security12bTitle
Common Stock , $0.001 par value
dei Trading Symbol
TradingSymbol
CYRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47234770
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
163891831
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
47060786
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7038733
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7098191
CY2020Q2 us-gaap Inventory Net
InventoryNet
538376
CY2019Q4 us-gaap Inventory Net
InventoryNet
473961
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
891652
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1096855
CY2020Q2 us-gaap Assets Current
AssetsCurrent
216686630
CY2019Q4 us-gaap Assets Current
AssetsCurrent
102964563
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13702732
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11833057
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5868513
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4460319
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4984012
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5177578
CY2020Q2 us-gaap Goodwill
Goodwill
10999722
CY2019Q4 us-gaap Goodwill
Goodwill
10999722
CY2020Q2 us-gaap Deposits Assets
DepositsAssets
534978
CY2019Q4 us-gaap Deposits Assets
DepositsAssets
437299
CY2020Q2 us-gaap Assets
Assets
252776587
CY2019Q4 us-gaap Assets
Assets
135872538
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6509745
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2498375
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1852186
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1903720
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
330272
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
367867
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
691386
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
665901
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
57946
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
24617
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9441535
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5460480
cyrx Convertible Subordinated Debt Discount
ConvertibleSubordinatedDebtDiscount
4000000.0
CY2020Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
110977419
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5497430
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4101236
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
146570
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
8539
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
56945
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
20935
CY2020Q2 us-gaap Liabilities
Liabilities
126119899
CY2019Q4 us-gaap Liabilities
Liabilities
9591190
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38565193
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37339787
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
38565
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37340
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
295423521
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
285609022
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169065602
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159319963
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
260204
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-45051
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
126656688
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
126281348
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
252776587
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135872538
CY2020Q2 us-gaap Revenues
Revenues
9389006
CY2019Q2 us-gaap Revenues
Revenues
8463588
us-gaap Revenues
Revenues
19163081
us-gaap Revenues
Revenues
15116500
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
4262010
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
4125199
us-gaap Cost Of Revenue
CostOfRevenue
8778121
us-gaap Cost Of Revenue
CostOfRevenue
7324210
CY2020Q2 us-gaap Gross Profit
GrossProfit
5126996
CY2019Q2 us-gaap Gross Profit
GrossProfit
4338389
us-gaap Gross Profit
GrossProfit
10384960
us-gaap Gross Profit
GrossProfit
7792290
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5733149
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3258781
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9763191
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5955640
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3292845
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2843073
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6374272
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5251065
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1946443
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
540933
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3679169
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1030529
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
10972437
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6642787
us-gaap Operating Expenses
OperatingExpenses
19816632
us-gaap Operating Expenses
OperatingExpenses
12237234
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5845441
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2304398
us-gaap Operating Income Loss
OperatingIncomeLoss
-9431672
us-gaap Operating Income Loss
OperatingIncomeLoss
-4444944
CY2020Q2 us-gaap Interest Expense
InterestExpense
398256
CY2019Q2 us-gaap Interest Expense
InterestExpense
333910
us-gaap Interest Expense
InterestExpense
400707
us-gaap Interest Expense
InterestExpense
672638
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
490784
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
119441
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
169598
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
210913
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5752913
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2518867
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9662781
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4906669
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49833
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9624
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
82858
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8724
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5802746
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2528491
us-gaap Net Income Loss
NetIncomeLoss
-9745639
us-gaap Net Income Loss
NetIncomeLoss
-4915393
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38281087
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31176166
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37914818
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30811109
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5802746
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2528491
us-gaap Net Income Loss
NetIncomeLoss
-9745639
us-gaap Net Income Loss
NetIncomeLoss
-4915393
CY2020Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
144647
CY2019Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-37905
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-335746
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-59612
CY2020Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
15563
CY2019Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
18913
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
26552
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
12846
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2795
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1535
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3939
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-11615
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-163005
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17457
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
305255
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
35151
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5965751
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2511034
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9440384
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4880242
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
38906938
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-2528491
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17457
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1959588
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
68807446
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
32167
CY2019Q2 cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
1555070
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
108750175
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
127304947
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-5802746
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-163005
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2280830
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20667
CY2020Q2 cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
3015995
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
126656688
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38546565
us-gaap Profit Loss
ProfitLoss
-4915393
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
35151
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3355824
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
68807446
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
49666
cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
2870916
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
108750175
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
126281348
us-gaap Profit Loss
ProfitLoss
-9745639
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
305255
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3880542
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
41333
cyrx Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
5893849
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
126656688
us-gaap Net Income Loss
NetIncomeLoss
-9745639
us-gaap Net Income Loss
NetIncomeLoss
-4915393
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1668710
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
797255
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
60105
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
30793
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
336578
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
75348
cyrx Realized Loss On Investments In Equity Securities
RealizedLossOnInvestmentsInEquitySecurities
804772
cyrx Realized Loss On Investments In Equity Securities
RealizedLossOnInvestmentsInEquitySecurities
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
16892
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
29911
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3921875
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3405490
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-121336
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-100254
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
33976
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
42042
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-25482
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
2594234
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
64415
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
85924
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-205203
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-225402
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
97679
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
14977
cyrx Right Of Use Asset Obtained In Exchange For Operating Leases Liability
RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability
-13485
cyrx Right Of Use Asset Obtained In Exchange For Operating Leases Liability
RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability
56532
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3149770
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1712648
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-51534
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
271779
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-37595
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-64830
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
36010
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-309608
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1251486
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2542151
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2578145
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
136252019
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6020660
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
19278866
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
2000000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
20429651
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
74934
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
43029
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119590238
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27071485
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5893849
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2870916
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
115000000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
68807446
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
3870500
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
19748
cyrx Repayment Of Finance Lease Liabilities
RepaymentOfFinanceLeaseLiabilities
32241
cyrx Repayment Of Finance Lease Liabilities
RepaymentOfFinanceLeaseLiabilities
11426
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
116991108
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71647188
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9129
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2908732
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43315088
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47234770
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37327125
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44326038
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80642213
cyrx Non Cash Net Unrealized Gain On Available For Sale Securities
NonCashNetUnrealizedGainOnAvailableForSaleSecurities
335746
cyrx Non Cash Net Unrealized Gain On Available For Sale Securities
NonCashNetUnrealizedGainOnAvailableForSaleSecurities
59612
cyrx Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings
ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings
26552
cyrx Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings
ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings
12846
cyrx Convertible Debt Costs Included In Accounts Payable And Accrued Liabilities
ConvertibleDebtCostsIncludedInAccountsPayableAndAccruedLiabilities
212186
cyrx Convertible Debt Costs Included In Accounts Payable And Accrued Liabilities
ConvertibleDebtCostsIncludedInAccountsPayableAndAccruedLiabilities
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
649414
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
cyrx Purchase Of Equipment Through Capital Lease Obligation
PurchaseOfEquipmentThroughCapitalLeaseObligation
204516
cyrx Purchase Of Equipment Through Capital Lease Obligation
PurchaseOfEquipmentThroughCapitalLeaseObligation
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport Inc. (“Cryoport”, “we”, or “our”) is a life sciences services company that is an integral part of the temperature-controlled supply chain supporting the biopharma, reproductive medicine and animal health markets. We are redefining logistics for the life sciences industry by providing a unique platform of critical solutions including highly differentiated temperature-controlled supply chain solutions, which include advanced packaging, informatics, specialty logistics services and biostorage services. Through our products, services and unparalleled expertise, we enable our clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport’s advanced platform, comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific) regions. Cryoport’s solutions are also designed to support pre-clinical, clinical trials, Biologics License Applications (BLA), Investigational New Drug Applications (IND) and New Drug Applications (NDA) with the FDA, as well as global clinical trials initiated in other countries, where strict regulatory compliance and quality assurance is mandated. Our industry standard setting Chain of Compliance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> solutions, which include vital analytics, such as ‘chain-of-condition’ and ‘chain-of-custody’ information in a single data stream, empower our clients’ continuous vigilance over their respective commodities. In addition, our Chain of Compliance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> standard ensures full traceability of the equipment used and the processes employed, further supporting each client’s goal of minimizing risk and maximizing success of their respective new biologics or other products and therapies as they are introduced into the global markets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 14, 2019, the Company acquired substantially all of the assets of Cryogene Partners, a Texas general partnership doing business as Cryogene Labs (“Cryogene”).  Cryogene operates a temperature-controlled biostorage solutions business in Houston, Texas.  As a result of the Cryogene acquisition, the Company operates in two reportable segments: Global Logistics Solutions and Global Bioservices. See Note 6 for segment information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
cyrx Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
P90D
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, fair value of assets acquired and liabilities assumed in business combinations, recoverability of goodwill and long- lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity-based instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including revenues, expenses, reserves and allowances, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at June 30, 2020 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly-rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly-rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p>
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
170000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
140000
CY2020Q2 cyrx Property Plant Equipment Ownership Percentage
PropertyPlantEquipmentOwnershipPercentage
0.19
CY2019Q4 cyrx Property Plant Equipment Ownership Percentage
PropertyPlantEquipmentOwnershipPercentage
0.19
CY2020Q2 cyrx Mechanical And Liquid Nitrogen Freezers Ownership Interest
MechanicalAndLiquidNitrogenFreezersOwnershipInterest
0.21
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2800
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3900
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P5Y
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
us-gaap Revenue Practical Expedient Initial Application And Transition Nondisclosure Of Transaction Price Allocation To Remaining Performance Obligation
RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation
true
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
330300
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
367900
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
76800
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
229600
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1500
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11600
CY2020Q2 us-gaap Revenues
Revenues
9389000
CY2019Q2 us-gaap Revenues
Revenues
8464000
us-gaap Revenues
Revenues
19163000
CY2020Q2 us-gaap Revenues
Revenues
9389000
CY2019Q2 us-gaap Revenues
Revenues
8464000
us-gaap Revenues
Revenues
19163000
us-gaap Revenues
Revenues
15117000
us-gaap Revenues
Revenues
15117000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5802746
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2528491
us-gaap Net Income Loss
NetIncomeLoss
-9745639
us-gaap Net Income Loss
NetIncomeLoss
-4915393
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38281087
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31176166
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37914818
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30811109
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9537564
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6357276
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9159973
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5813329
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2020Q2 us-gaap Cash
Cash
16969290
CY2019Q4 us-gaap Cash
Cash
3546893
CY2020Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
27356748
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
43687877
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44326038
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47234770
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
163891831
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
47060786
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
208217869
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
94295556
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
149225205
CY2020Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
324539
CY2020Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
42904
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
149506840
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
134131660
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
134133950
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
15093545
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
15372890
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
149225205
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
149506840
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21121659
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
26552
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
54111
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21094100
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
12043525
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
12046700
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
9078134
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
9047400
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21121659
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21094100
CY2020Q2 us-gaap Debt And Equity Securities Realized Gain Loss Excluding Other Than Temporary Impairment
DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment
4900
us-gaap Debt And Equity Securities Realized Gain Loss Excluding Other Than Temporary Impairment
DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment
16900
CY2020Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
14400000
cyrx Capital Expenditure Operations
CapitalExpenditureOperations
-3396852
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-468194
cyrx Equity Securities Realized Gain Loss Sold
EquitySecuritiesRealizedGainLossSold
-804772
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
336578
CY2020Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
95200000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2020Q2 us-gaap Revenues
Revenues
9389006
CY2020Q2 us-gaap Interest Expense
InterestExpense
398256
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
844281
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5845441
CY2020Q2 us-gaap Assets
Assets
252776587
CY2020Q2 us-gaap Goodwill
Goodwill
10999722
CY2020Q2 cyrx Capital Expenditure Operations
CapitalExpenditureOperations
-1989287
us-gaap Revenues
Revenues
19163081
us-gaap Interest Expense
InterestExpense
400707
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1668710
us-gaap Operating Income Loss
OperatingIncomeLoss
-9431672
CY2020Q2 us-gaap Assets
Assets
252776587
CY2020Q2 us-gaap Goodwill
Goodwill
10999722
CY2020Q2 us-gaap Goodwill
Goodwill
11000000.0
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5613137
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
629125
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4984012
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5538203
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
360625
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5177578
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
134250
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
268500
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
44800
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
44800
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
268500
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
537000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
537000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
537000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
432000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2386750
CY2020Q2 cyrx Future Amortization Of Finite Lived Intangible Assets
FutureAmortizationOfFiniteLivedIntangibleAssets
4698250
CY2020Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
115000000.0
CY2020Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0300
CY2020Q2 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
3700000
CY2020Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0300
cyrx Interest Amount On Acounts Payable And Accured Liabilities
InterestAmountOnAcountsPayableAndAccuredLiabilities
335400
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
4810002
us-gaap Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
41.8261
CY2020Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
23.91
cyrx Debt Instrument Convertible Threshold Maximum Conversion Ratio
DebtInstrumentConvertibleThresholdMaximumConversionRatio
48.10
cyrx Debt Instrument Redemption Threshold Percentage Of Stock Price Trigger
DebtInstrumentRedemptionThresholdPercentageOfStockPriceTrigger
130
cyrx Debt Instrument Redemption Threshold Trading Days
DebtInstrumentRedemptionThresholdTradingDays
20
cyrx Debt Instrument Redemption Threshold Consecutive Trading Days
DebtInstrumentRedemptionThresholdConsecutiveTradingDays
30
cyrx Debt Instrument Percentage Of Aggregate Principal Amount Held By Note Holders Liable To Declare Principal Amount Of Notes To Be Due And Payable Immediately By Notice To Company
DebtInstrumentPercentageOfAggregatePrincipalAmountHeldByNoteHoldersLiableToDeclarePrincipalAmountOfNotesToBeDueAndPayableImmediatelyByNoticeToCompany
25
CY2020Q2 us-gaap Long Term Debt Term
LongTermDebtTerm
P5Y
CY2020Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0374
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
115000000
CY2020Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4022581
CY2020Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
110977419
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
335417
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
60105
us-gaap Interest Expense Debt
InterestExpenseDebt
395522
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5011
cyrx Finance Lease Cost
FinanceLeaseCost
22911
us-gaap Lease Cost
LeaseCost
623931
cyrx Long Term Debt Maturities Repayments Of Principal In Year Six
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix
115000000
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
115000000
cyrx Debt Instrument Registration Default Threshold Maximum Combined Interest Rate
DebtInstrumentRegistrationDefaultThresholdMaximumCombinedInterestRate
0.50
cyrx Debt Instrument Registration Default Cash Payment To Each Noteholder Percentage
DebtInstrumentRegistrationDefaultCashPaymentToEachNoteholderPercentage
3
cyrx Lessee Option To Extend
LesseeOptionToExtend
P5Y
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
269400
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
71000
cyrx Finance Lease Rightofuse Asset Accumulated Depreciation
FinanceLeaseRightofuseAssetAccumulatedDepreciation
46900
CY2019 cyrx Finance Lease Rightofuse Asset Accumulated Depreciation
FinanceLeaseRightofuseAssetAccumulatedDepreciation
22800
us-gaap Operating Lease Cost
OperatingLeaseCost
601020
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
17900
us-gaap Operating Lease Payments
OperatingLeasePayments
587535
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
20300
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
17500
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1804281
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
202619
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2020Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.067
CY2020Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.054
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
860504
CY2020Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
42109
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2036899
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
65357
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2105754
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
56710
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1574928
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
58583
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1469719
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1099779
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4497242
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13644825
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
222759
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7456009
CY2020Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
18243
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6188816
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
204516
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
691386
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
57946
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5497430
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
146570
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6188816
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
204516
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
41300
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
49700
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8000000.0
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7969007
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
4810002
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
15000000.0
cyrx Warrants Exercised Intrinsic Value
WarrantsExercisedIntrinsicValue
11600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.773
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.698
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2301497
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1991755
us-gaap Share Based Compensation
ShareBasedCompensation
3921875
us-gaap Share Based Compensation
ShareBasedCompensation
3405490
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7100000

Files In Submission

Name View Source Status
0001104659-20-092668-index-headers.html Edgar Link pending
0001104659-20-092668-index.html Edgar Link pending
0001104659-20-092668.txt Edgar Link pending
0001104659-20-092668-xbrl.zip Edgar Link pending
cyrx-20200630.xsd Edgar Link pending
cyrx-20200630x10q.htm Edgar Link pending
cyrx-20200630x10q004.jpg Edgar Link pending
cyrx-20200630x10q_htm.xml Edgar Link completed
cyrx-20200630xex31d1.htm Edgar Link pending
cyrx-20200630xex31d2.htm Edgar Link pending
cyrx-20200630xex32d1.htm Edgar Link pending
cyrx-20200630_cal.xml Edgar Link unprocessable
cyrx-20200630_def.xml Edgar Link unprocessable
cyrx-20200630_lab.xml Edgar Link unprocessable
cyrx-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending